SavedAdd your journal

Journals / Gülhane Tıp Dergisi / 2020 / Cilt: 62 - Sayı: 3

Can Increased or Decreased COX2 and P21 Expression be Used in Illness Monitoring of Gastric Cancer and Its Potential Precursor Lesions?

Sait YEŞİLLİK
Melih ALÖMEROĞLU
Birol YILDIZ
Bilgin Bahadır BAŞGÖZ
Mustafa GÜLŞEN
Pages
151–156
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Increased COX2, expression, especially in atrophic gastritis patients, and decreased P21 expression may be used in the follow-up of patients with gastric cancer and its precursor lesions.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aims: Early diagnosis and treatment can improve the prognosis of patients with gastric cancer.
📊
Key Findings & Data:Methods: In our study, cyclooxygenase-2 (COX2) and P21 expressions of the patients with gastric adenocarcinoma and its precursor lesions atrophic gastritis and intestinal metaplasia were examined retrospectively with the immunohistochemical method.
💡
Conclusion & Impact:Increased COX2, expression, especially in atrophic gastritis patients, and decreased P21 expression may be used in the follow-up of patients with gastric cancer and its precursor lesions.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Aims: Early diagnosis and treatment can improve the prognosis of patients with gastric cancer. Therefore, identification and follow-up of patients who are under the risk of gastric cancer can improve the success of treatment and quality of life. Methods: In our study, cyclooxygenase-2 (COX2) and P21 expressions of the patients with gastric adenocarcinoma and its precursor lesions atrophic gastritis and intestinal metaplasia were examined retrospectively with the immunohistochemical method. Results: Forty patients were enrolled in each group. Grade and intensity of COX2 expressions were high in all three groups in accordance with the literature. In contrast with COX2 expressions, the grade and intensity of P21 expressions were very low in all three groups. Expressions of P21 were not observed in the vast majority of the gastric cancer group. Due to slight expressions, we detected statistically significant differences in both grading and intensity of P21 expressions between precancerous lesions and gastric cancer. Conclusions: High COX2 expressions were consistent with literature. Decreased P21 expressions can reveal the relationship between loss of P21 expression and poor prognosis. Increased COX2, expression, especially in atrophic gastritis patients, and decreased P21 expression may be used in the follow-up of patients with gastric cancer and its precursor lesions.

🔖

Cite This Article

YEŞİLLİK, S., ALÖMEROĞLU, M., YILDIZ, B., BAŞGÖZ, B. B., GÜLŞEN, M. (2020). Can Increased or Decreased COX2 and P21 Expression be Used in Illness Monitoring of Gastric Cancer and Its Potential Precursor Lesions?. Gülhane Tıp Dergisi, Cilt: 62 - Sayı: 3, 151–156. https://ajindex.com/articles/159644

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Eberhart CE, Dubois RN. Eicosanoids and the gastrointestinal tract. Gastroenterology. 1995;109:285-301.
  2. Lim HY, Joo HJ, Choi JH, et al. Increased expression of cycloxygenase-2 protein in human gastric carcinoma. Clin Cancer Res. 2000;6:519-525.
  3. Mizuno H, Sakomoto C, Matsuda K, et al. Induction of cyclooxygenase-2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing mice. Gastroenterology. 1997;112:387-397.
  4. Van Rees BP, Saukkonen K, Ristimaki A, et al. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol. 2002;196:171-179.
  5. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. yclooxygenase 2 expression in Barrett’s esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology. 2000;118:487- 496. Türkmen IÇ, Başsüllü N, Uraz S, Yerdel MA, Memışoğlu R, Bülbül Doğusoy G. CDX2, COX2 and MUC2 expressions in Barrett’s esophagus; Can they be useful in determination of the dysplasia. Turk Patoloji Derg. 2012;28:251-258.
  6. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The P21, interacting protein Cip 1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75:805-816.
  7. Czerniak B, Herz F, Koss LG, Schlom J. Ras oncogene as P21 as a tumor marker in cytodiagnosis of gastric and colonic carcinomas. Cancer. 1987;60:2432-2436.
  8. Ristimaki A, Sivula A, Ludin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002;62:632-635.
  9. Kimura A, Tsuji S, Tsujii M, et al. Expression of COX2 and nitrotyrosine in human gastric mucosa before and after Helicobacter Pylori eradication. Prostaglandins Leukot Essent Fatty Acids. 2000;63:315-322.
  10. Saukkonen K, Nieminen O, Van Rees B, et al. Expression of COX2 in the dysplasia of the stomach and in intestinal type gastric adenocarcinoma. Clin Cancer Res. 2001;7:1923-1931.
  11. Rossolymos NA, Papatheodoridis G, Tsakoniatis M, Dimitrios K, Lazaris A. Expression of cyclooxygenase-2 in gastritis and gastric premalignant lesions. Ann Gastroenterol. 2013;26:275. Wang J, Chi DS, Kalin GB, et al. Helicobacter Pylori infection and oncogene expressions in gastric cancer and its precursor lesions. Dig Dis Sci. 2002;47:107-113.
  12. Sun Y, Li JY, He JS, Zhou LX, Chen K. Tissue microarray analysis of multiple gene expression in intestinal metaplasia, dysplasia, and carcinoma of the stomach. Histopathology. 2005;46:505-514.
  13. Noguchi M, Hirohashi S, Shimosato Y, et al. Histologic demonstration